- Home
- MSD vs PBYI Comparison
MSD vs PBYI Comparison
Compare MSD & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSD
- PBYI
- Stock Information
- Founded
- MSD 1993
- PBYI 2010
- Country
- MSD United States
- PBYI United States
- Employees
- MSD N/A
- PBYI N/A
- Industry
- MSD Trusts Except Educational Religious and Charitable
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- MSD Finance
- PBYI Health Care
- Exchange
- MSD Nasdaq
- PBYI Nasdaq
- Market Cap
- MSD 159.9M
- PBYI 145.3M
- IPO Year
- MSD N/A
- PBYI N/A
- Fundamental
- Price
- MSD $8.11
- PBYI $2.91
- Analyst Decision
- MSD
- PBYI Strong Buy
- Analyst Count
- MSD 0
- PBYI 1
- Target Price
- MSD N/A
- PBYI $7.00
- AVG Volume (30 Days)
- MSD 70.2K
- PBYI 289.1K
- Earning Date
- MSD 01-01-0001
- PBYI 02-27-2025
- Dividend Yield
- MSD 11.26%
- PBYI N/A
- EPS Growth
- MSD N/A
- PBYI 492.79
- EPS
- MSD N/A
- PBYI 0.47
- Revenue
- MSD N/A
- PBYI $243,569,000.00
- Revenue This Year
- MSD N/A
- PBYI N/A
- Revenue Next Year
- MSD N/A
- PBYI N/A
- P/E Ratio
- MSD N/A
- PBYI $6.24
- Revenue Growth
- MSD N/A
- PBYI 6.30
- 52 Week Low
- MSD $6.11
- PBYI $2.23
- 52 Week High
- MSD $7.46
- PBYI $7.15
- Technical
- Relative Strength Index (RSI)
- MSD 58.92
- PBYI 48.76
- Support Level
- MSD $7.95
- PBYI $2.69
- Resistance Level
- MSD $8.14
- PBYI $2.98
- Average True Range (ATR)
- MSD 0.11
- PBYI 0.12
- MACD
- MSD -0.01
- PBYI 0.01
- Stochastic Oscillator
- MSD 66.00
- PBYI 58.11
About MSD Morgan Stanley Emerging Markets Debt Fund Inc.
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.